Todd Richard Elworthy

This inventor holds 23 USPTO granted patents, plus 2 CIPO patents and 8 EPO patents, primarily in Antiviral Compounds. Top assignees: Roche Palo Alto LLC, Syntex (u.s.a.) Inc., Other. Active years: 1995-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Todd Richard Elworthy. Retrieved from https://idiyas.com/inventor/todd-richard-elworthy

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23

% Patents Active = 56.5

CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 8 (Patent Applications = 8)

Average Co-Inventor Count = 4.8

ph-index = 8

Forward Citations = 335(Granted Patents)

Location History:

Palo Alto, CA (US) (1995 - 1999)
Los Gatos, CA (US) (2005 - 2012)
Los Altos, CA (US) (2011 - 2012)

Company Filing History:

1 out of 834,513

Other

patents

Years Active: 1995-2012

Loading Chart...

Areas of Expertise:

Heterocyclic Compounds

Nicotinic Alpha 7 Modulators

Pyrrolopyrazine Inhibitors

Non-Nucleoside Reverse Transcriptase Inhibitors

Prostaglandin Agonists

Mycophenolic Acid Derivatives

Tetrazole-Substituted Aryl Amides

Pyrimidinedione

Thio and Oxy-Pyridine

2-Piperidone Derivatives

Antiviral Agents

Chemical Derivatives

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8293778 - Heterocyclic antiviral compounds (2012-10-23),

2. 8198332 - Salicylamide derivatives as nicotinic alpha 7 modulators (2012-06-12),

3. 8119636 - Pyrrolopyrazine kinase inhibitors (2012-02-21),

4. 8008298 - Pyrrolopyrazine kinase inhibitors (2011-08-30),

5. 7981914 - Tetrazole-substituted aryl amide derivatives and uses thereof (2011-07-19),

6. 7947709 - Non-nucleoside reverse transcriptase inhibitors (2011-05-24),

7. 7939531 - Pyrrolopyrazine kinase inhibitors (2011-05-10),

8. 7902197 - Pyrrolopyrazine kinase inhibitors (2011-03-08),

9. 7666891 - Heterocyclic antiviral compounds (2010-02-23),

10. 7288542 - Non-nucleoside reverse transcriptase inhibitors (2007-10-30),

11. 7271183 - 2-Piperidone derivatives as prostaglandin agonists (2007-09-18),

12. 6900336 - 8-aza-11-deoxy prostaglandin analogues (2005-05-31),

13. 6849657 - 2-pyrrolidone derivatives as prostanoid agonists (2005-02-01),

14. 5859014 - Pyrimidinedione, pyrimidinetrione, triazinedione and (1999-01-12),

15. 5688795 - �3-(4-phenylpiperazin-1-yl)propyl-amino, thio and oxy!-pyridine, (1997-11-18),

Title: Todd Richard Elworthy: Innovator in Antiviral Compounds

Introduction

Todd Richard Elworthy is a notable inventor based in Los Altos, California, recognized for his significant contributions to the field of pharmaceutical sciences, specifically in the development of antiviral compounds. With a remarkable portfolio of 23 patents, he continues to push the boundaries of innovation in treating complex viral infections.

Latest Patents

Among his latest inventions, one noteworthy patent involves the creation of heterocyclic antiviral compounds designed to combat HIV-1 infections. This patent outlines a method of treatment using compounds characterized by a specific formula (Formula I) where various substituents (R) are defined in detail. Another recent patent by Elworthy focuses on salicylamide derivatives, which act as nicotinic alpha 7 modulators. This application not only discloses specific compounds of Formula I but also includes pharmaceutical compositions and methods for their use and preparation.

Career Highlights

Throughout his career, Todd Elworthy has worked with prestigious organizations such as Roche Palo Alto LLC and Syntex (U.S.A.) Inc. His tenure at these companies allowed him to contribute to cutting-edge research in pharmaceuticals, particularly in the realms of antiviral and neurological treatments. His contributions to the field are supported by his innovative patents, which serve as critical resources in ongoing research and development.

Collaborations

Elworthy has had the opportunity to collaborate with esteemed colleagues, including David Bernard Smith and David John Morgans, Jr. These collaborations have likely fostered a rich exchange of ideas and expertise, further enhancing the innovative nature of his work.

Conclusion

Todd Richard Elworthy's dedication to advancing pharmaceutical innovation and his impressive number of patents highlight his role as a key figure in the ongoing battle against viral infections. His innovative approaches and collaborative spirit continue to inspire and shape the future of antiviral therapy and drug development.

Profile summary based on public USPTO records.